ChemInform Abstract: Chemistry of Binuclear Rhenium Clusters

Shtemenko, A. V.; Bovykin, B. A.

doi:10.1002/chin.199818296

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A common procedure for the synthesis of dirhenium(III) carboxylates involving the reduction of perrhenate ions in the presence of a corresponding acid (using Sn II , NaH 2 PO 2 or Ph 3 P as the reducing agents) 9, 13 was insufficient for the preparation of the aminocarboxylate complex due to the high solubility of the product. Therefore the proposed route (Scheme 1) includes isolation of the ionic derivative [GABAH] 2 Re 2 Cl 8 (I) as a suitable starting material 14 followed by the interconversion of the GABAH + cation to the inner sphere carboxylate ligand with the loss of HCl.…”

Section: Synthesis and Propertiesmentioning

confidence: 99%

Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin

Shtemenko

Collery²,

Штеменко³

et al. 2009

Dalton Trans.

View full text Add to dashboard Cite

A new dirhenium(III) complex cis-[Re2(GABA)2Cl5(H2O)]Cl.2H2O with zwitterionic gamma-aminobutyrate ligands was prepared and characterized by spectral methods and crystallography. The structure of the compound is comprised of dinuclear complex cations (Re-Re 2.2437(3) A) involving cis-oriented double carboxylate bridges, four equatorial chloride ions and two weakly bonded aqua and chloride ligands in the axial positions at two rhenium centers (Re-O 2.363(3), Re-Cl 2.6735(12) A). Antitumor properties of the complex were studied in the model of tumor growth with the use of Wistar rats inoculated by tumor carcinoma Guerink cells. The introduction of the compound in dosage according to the scheme of antioxidant therapy, inhibited the tumor growth by ca. 60% and led to stabilization of red blood cells in the tumor-bearing organisms. The combined introduction of the compound and cisplatin had a significant impact on the tumor growth and the disappearance of the tumors in most of the animals.

show abstract

Section: Synthesis and Propertiesmentioning

confidence: 99%

Synthesis, characterization, in vivo antitumor properties of the cluster rhenium compound with GABA ligands and its synergism with cisplatin

Shtemenko

Collery²,

Штеменко³

et al. 2009

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…In this research the starting complex was synthesized without using the autoclave method, by boiling equimolar quantities of tetrabutylammonium octahlorodirhenate(III) ([(N(Bu) 4 ) 2 Re 2 Cl 8 ]) in the corresponding acid under inert atmosphere. The purity of the complexes was checked by spectrophotometry [8].…”

Section: Methodsmentioning

confidence: 99%

Polymetallic copper-rhenium composite material

Iziumskyi¹,

Melnyk²,

Shtemenko³

2013

Chem. Met. Alloys

View full text Add to dashboard Cite

A method to obtain new copper-rhenium composites on a steel substrate using a complex of dirhenium(III) cis-tetrachlorodi-µ-propionate with axial N,N-dimethylacetamide (cis-[Re 2 Cl 4 (C 2 H 5 COO) 2 (DMAA) 2 ]) and copper metal as starting materials for low-temperature chemical vapor deposition, was investigated. The obtained copper-rhenium composite was studied by scanning electron microscopy and X-ray spectroscopy. According to the elemental analysis the composite contained 71.53% Fe, 25.45% Cu, 1.99% Re, and 1.04% Sn.

show abstract

“…Матеріал і методи досліджень У ході експерименту вивчали кластерну сполуку ренію з адамантильним ліган-дом cis-Re 2 (C 10 H 15 COO) 2 Cl 4 ·2DMSO (Re2d), синтезовану на кафедрі неорганічної хімії Українського державного хіміко-технологічного університету [19].…”

Section: вступunclassified